Recent News

• 06.08.2026 - U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT AFFIRMS VICTORY FOR CORMEDIX THERAPEUTICS IN MINOCIN® PATENT LITIGATION
• 05.05.2026 - CORMEDIX THERAPEUTICS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 14, 2026
• 04.27.2026 - CORMEDIX THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE III RESPECT TRIAL ASSESSING REZZAYO® FOR THE PROPHYLAXIS OF INVASIVE FUNGAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS
• 04.07.2026 - CORMEDIX TO PARTICPATE IN NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
• 03.05.2026 - CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Recent Filings

• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.14.2026 - EX-99.1 EX-99.1
• 05.14.2026 - 8-K Current report
• 04.29.2026 - DEF 14A Other definitive proxy statements
• 04.29.2026 - ARS Annual Report to Security Holders
• 04.29.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.27.2026 - EX-99.1 EX-99.1
• 04.27.2026 - 8-K Current report
• 04.17.2026 - PRE 14A Other preliminary proxy statements